BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C comb

In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virolo

Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compar

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical

Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Health

Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026More Than 880 HCV Treatment-Naïv

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naï

Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, whic

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed co

Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data e

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)

Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion o

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript

Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which beat the ana

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company)

Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX

Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and Atea Pharmaceuticals (NASDAQ: AVIR - Get Fre

Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Ou

Atea Pharmaceuticals (NASDAQ: AVIR) outlined progress in its hepatitis C (HCV) late-stage developmen

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which missed the a

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Result

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus  Initiation of Pha

In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWA

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.53) per share which missed the a

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical compa

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical compa

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.44) per share which missed the a

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical compa

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which beat the ana

 Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatme

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatmen

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal

Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase

Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.40) per share which missed the a

Global Phase 3 HCV Program Expected to Initiate in 1Q 2025Potential Best-in-Class Profile of Bemnifo